BMC cardiovascular disorders · 2025
Effect of carperitide on clinical outcomes among patients with acute heart failure: a meta-analysis of randomized and propensity‑matched studies.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shiga Tsuyoshi, Suzuki Atsushi, Inoue Sachie, Hashiguchi Masayuki
Аннотация
BACKGROUND: Carperitide, which is an α-human A-type natriuretic peptide, is used intravenously for the treatment of acute heart failure (AHF) primarily in Japan. However, its clinical effectiveness has not been established. The aim of this meta-analysis was to assess the effect of carperitide on the clinical outcomes of patients with AHF.
METHODS: We searched the MEDLINE, ICHUSHI, Cochrane Library and Web of Science databases using a defined search strategy to identify eligible randomized controlled trials (RCTs) and propensity score matching (PSM) studies. The primary outcome was in-hospital mortality. The secondary outcomes were long-term mortality, HF rehospitalization, length of hospital stay and hypotension. Pooled odds ratios (ORs)/mean differences and 95% confidence intervals (CIs) were calculated by using the random effects model.
RESULTS: A total of nine studies were evaluated in the meta-analysis, including four RCTs and five PSM studies. A meta-analysis of RCTs and PSM studies revealed that the in-hospital mortality rate was higher in the carperitide group than in the noncarperitide group (OR 1.38; 95% CI 1.07-1.78; I2 = 77%). However, a meta-analysis of the RCTs alone revealed no significant difference in in-hospital mortality (OR 0.85; 95% CI: 0.07-10.49; I2 = 39%). There were no significant differences observed between the two groups in terms of long-term mortality, HF rehospitalization, incidence of hypotension, or length of hospital stay.
CONCLUSIONS: This meta-analysis suggested that carperitide therapy may not be superior to noncarperitide therapy in terms of reducing in-hospital mortality rates or improving long-term outcomes in patients with AHF.
TRIAL REGISTRATION: The review protocol was registered in PROSPERO (ID: CRD420251071777).
METHODS: We searched the MEDLINE, ICHUSHI, Cochrane Library and Web of Science databases using a defined search strategy to identify eligible randomized controlled trials (RCTs) and propensity score matching (PSM) studies. The primary outcome was in-hospital mortality. The secondary outcomes were long-term mortality, HF rehospitalization, length of hospital stay and hypotension. Pooled odds ratios (ORs)/mean differences and 95% confidence intervals (CIs) were calculated by using the random effects model.
RESULTS: A total of nine studies were evaluated in the meta-analysis, including four RCTs and five PSM studies. A meta-analysis of RCTs and PSM studies revealed that the in-hospital mortality rate was higher in the carperitide group than in the noncarperitide group (OR 1.38; 95% CI 1.07-1.78; I2 = 77%). However, a meta-analysis of the RCTs alone revealed no significant difference in in-hospital mortality (OR 0.85; 95% CI: 0.07-10.49; I2 = 39%). There were no significant differences observed between the two groups in terms of long-term mortality, HF rehospitalization, incidence of hypotension, or length of hospital stay.
CONCLUSIONS: This meta-analysis suggested that carperitide therapy may not be superior to noncarperitide therapy in terms of reducing in-hospital mortality rates or improving long-term outcomes in patients with AHF.
TRIAL REGISTRATION: The review protocol was registered in PROSPERO (ID: CRD420251071777).